Ren Jie, Liu Jianlan, Yu Nanze, Zhang Wenchao, Qian Hui, Liu Zhifei, Zhu Ningwen
Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
Department of Plastic Surgery, Peking Union Medical Hospital, Chinese Academy of Medical Sciences, Beijing, China.
J Cosmet Dermatol. 2019 Oct;18(5):1487-1494. doi: 10.1111/jocd.13071. Epub 2019 Jul 26.
Regenerative Epithelial Suspension can lead to the restoration of wound and repigmentation, which can be gained by ReCell medical device to treat scar and depigmentation diseases.
To report the effectivity of ReCell combined with microdermabrasion in scar and depigmentation diseases and review the literature of this new technology.
We gave a differential donor⁄recipient ratio of about 1:20-30 with vitiligo, 1:40 with postburn construction, 1:80 with acne scar, and 1:120 with adult congenital melanocytic nevus, 1:80 with pediatrics, respectively. Photographs of patients before treatment and 3 months following the last treatment session were used to evaluate the effectivity.
A total of 8 patients including vitiligo vulgaris, postburn reconstruction, acne scars, and congenital melanocytic nevi treated by ReCell technology combined with microdermabrasion showed significant improvement in skin texture and color. And 17 studies of the research on ReCell technology were totally included in the systematic review.
Our investigation showed that Regenerative Epithelial Suspension gained by ReCell technology combined with microdermabrasion may improve scar and depigmentation diseases.
再生上皮悬浮液可促进伤口愈合和色素沉着恢复，可通过ReCell医疗器械治疗瘢痕和色素脱失性疾病。
报告ReCell联合微晶磨皮术治疗瘢痕和色素脱失性疾病的有效性，并综述该新技术的相关文献。
对于白癜风患者，供体与受体比例约为1:20 - 30；烧伤后整形患者为1:40；痤疮瘢痕患者为1:80；成人先天性黑素细胞痣患者为1:120，儿科患者为1:80。使用患者治疗前及最后一次治疗后3个月的照片评估疗效。
8例接受ReCell技术联合微晶磨皮术治疗的患者，包括寻常型白癜风、烧伤后整形、痤疮瘢痕和先天性黑素细胞痣，皮肤质地和颜色均有显著改善。系统评价共纳入17项关于ReCell技术的研究。
我们的研究表明，ReCell技术联合微晶磨皮术获得的再生上皮悬浮液可能改善瘢痕和色素脱失性疾病。
